However, it is currently unknown if HER2DX, in the absence of cytotoxic therapy, can predict response to trastuzumab-pertuzumab, the only approved anti-HER2 drug combination in early-stage HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.